Abstract Library

#506 Paraneoplastic Neurological Syndrome in a Patient with a Pancreatic Well-Differentiated Endocrine Tumor

Introduction: Few studies report the association of neurological syndromes with a carcinoid, the majority being small-cell lung cancer.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Brizzi M, Ferrero A, Ottone A, Bellini E, Bitossi R,

Keywords: paraneoplastic syndrome,

#335 Dosimetry with 111In-octreotide and Coinfusion of Amino Acids in the Prediction of Nephrotoxicity in Neuroendocrine Tumors after PRRT with 90Y-DOTATOC

Introduction: Kidneys are the critical organs in PRRT. A dosimetry protocol was implemented in an ongoing study to estimate the biological effective dose (BED) on the kidneys after 90Y-DOTATOC therapy.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Van Binnebeek S, Baete K, Vanbilloen B, Terwinghe C, Mottaghy F,

Keywords: PRRT, 90y-DOTATOC, dosimetry, 111in-octreotide, amino acids,

#289 Gallium-68 DOTATATE PET CT Frequently Changes Patient Management or Staging When Compared with Indium-111 Octreotide in the Assessment of Neuroendocrine Tumors

Introduction: 68Ga-DOTATATE PET CT offers higher resolution than previous octreotide-labelled scintigraphic techniques, and the literature suggests increased sensitivity for the localization and staging of NETs.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Carroll R, Comminos A, Frilling A, Meeran K, Al-Nahhas A,

Keywords: Gallium-68 DOTATATE PET CT, Indium-111 Octreotide, neuroendocrine tumor,

#153 Antibody formation against somatostatin analogues with altered biodistribution and dosimetry: a case with implications for PRRT

Introduction: Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors (NETs) has emerged as a powerful palliative therapy. I.v. administration of radiolabeled (e.g. Yttrium-90) somatostatin analogues (SA) results in high-dose local irradiation of all tumor sites. The radiolabelled SA accumulates in the tumors through receptor-mediated internalization depending on the expression of somatostatin receptors and the pharmacokinetics of the radiolabelled SA.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author: VAN BINNEBEEK S

Authors: Van Binnebeek S, DeRoose C, Van Billoen B, Baete K, Mortelmans L,

Keywords: antibody, somatostatin analogue, 90Y-DOTATOC, dosimetry, PRRT, 68Ga-DOTATOC,

#114 Downstaging of a gastroenteropancreatic neuroendocrine tumor after combination therapy of temozolomide, Bevacizumab and long-acting somatostatin analogs

Introduction: Patients with gastroenteropancreatic endocrine (GEP) tumors and progressive disease have been treated with several chemotherapeutic regimens with variable responses and considerable toxicity. Recent studies have shown that GEP tumors may respond to therapy with anti-angiogenic agents, mainly as a result of their increased vascularity.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author: KALTSAS G

Authors: Antoniou S, Kanakis G, Zilos A, Thomas D, Tzavaris N,

Keywords: GEPNETs, temozolomide, bevacizumab, somatostatin analogue,